Eli Lilly and Company / Shanghai Junshi Biosciences Co., Ltd.

COVID-19 prevention and treatment (SARS-CoV-2 neutralizing monoclonal antibody)

30M US cases/yr · $5.8B US COVID-19 therapeutic mAb spend 2021 (USD MM, peak year) · 1100000 Cumulative US COVID-19 deaths through 2023

Disease Overview

COVID-19, caused by the novel coronavirus SARS-CoV-2, was declared a pandemic by the WHO on 11 March 2020. By the time of this deal (May 2020), the United States had already recorded ~1.2 million confirmed cases and ~70,000 deaths, with case rates climbing in major metropolitan areas and a national emergency declaration in place since March 13. Total cumulative US cases ultimately exceeded 100 million through 2023, with ~1.1 million US deaths reported by CDC. At deal date, no FDA-approved or authorized therapeutics or vaccines existed for SARS-CoV-2 — only supportive care, off-label hydroxychloroquine (later debunked), and remdesivir under emergency expanded access (Veklury received EUA on May 1, 2020, days before this deal). Neutralizing monoclonal antibody (mAb) approaches targeting the SARS-CoV-2 spike receptor-binding domain (RBD) emerged as a promising therapeutic class for early treatment in high-risk outpatients and post-exposure prophylaxis. The unmet need was acute: treatment options for the elderly, immunocompromised, and those with co-morbidities were essentially non-existent in May 2020, and the operational urgency of the pandemic compressed normal R&D timelines from years to months.

Competitive Landscape

In early May 2020, the SARS-CoV-2 neutralizing antibody field was a sprint among multiple Big Pharma and biotech entrants. Direct competitors included Regeneron's REGN-COV2 (casirivimab + imdevimab cocktail, derived from VelocImmune mice and convalescent patient B-cells, IND filed June 2020, EUA Nov 2020), Vir Biotechnology + GSK's sotrovimab (VIR-7831, derived from a 2003 SARS survivor's memory B-cells, EUA May 2021), AstraZeneca's tixagevimab + cilgavimab (Evusheny/AZD7442, EUA Dec 2021 for prophylaxis), and Brii Biosciences' amubarvimab + romlusevimab. Lilly later partnered with AbCellera on bamlanivimab (LY-CoV555) which received EUA Nov 2020 — etesevimab (the Junshi-derived antibody) was authorized in combination with bamlanivimab Feb 2021. Adjacent therapeutic categories competing for COVID-19 share included antivirals (Gilead remdesivir/Veklury, Pfizer Paxlovid/nirmatrelvir-ritonavir EUA Dec 2021, Merck molnupiravir/Lagevrio EUA Dec 2021), and immunomodulators (Roche tocilizumab/Actemra, Lilly baricitinib/Olumiant for severe disease). Most COVID-19 mAbs lost activity against Omicron BA.1/BA.2 in late 2021/early 2022, with FDA pulling EUAs progressively through 2022.